What is ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study?
Category: Others
See also: Cyclophosphamide Rituximab
ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study is a randomized, double Blind controlled trial comparing rituximab against cyclophosphamide in patients with connective tissue disease associated interstitial lung disease. NCT01862926
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Interstitial lung disease | 1 | 8 | |
| Mixed connective tissue disease | 1 | 8 | |
| Raynaud's disease | 1 | 8 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 1 | |
| Moderate | 4 | |
| Mild | 0 | |
| None | 3 |
Commonly reported side effects and conditions associated with ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study
| Side effect | Patients | Percentage |
|---|---|---|
| Fatigue | 1 | |
| Muscle pain | 1 | |
| Muscle tightness | 1 | |
| Nausea | 1 |
Why patients stopped taking ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Course of treatment ended | 1 |
Duration
Stopped using ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study
| Duration | Patients | Percentage |
|---|---|---|
| 1 - 6 months | 1 |
What people switch to and from
Patients started using ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Methylprednisolone (Solu-Medrol Infusion) | 1 |
Last updated: